CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC

C. Grohe; B. E. Johnson; T. M. Kim; T. J. N. Hiltermann; F. Barlesi; Y. Goto; O. Gunnarsson; T. Overbeck; N. Reguart; M. Wermke; G. de Castro; E. Felip; A. Greystoke; B. J. Solomon; S. Deudon; A. -L. Louveau; V. Passos; D. S. W. Tan

CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC

C. Grohe, B. E. Johnson, T. M. Kim, T. J. N. Hiltermann, F. Barlesi, Y. Goto, O. Gunnarsson, T. Overbeck, N. Reguart, M. Wermke, G. de Castro, E. Felip, A. Greystoke, B. J. Solomon, S. Deudon, A. -L. Louveau, V. Passos, D. S. W. Tan

Translational Immunology Groningen (TRIGR)

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Pages (from-to)	152-152
Number of pages	1
Journal	Oncology Research and Treatment
Volume	43
Issue number	SUPPL 4
Publication status	Published - Oct-2020

Handle.net

Persistent link

Cite this

Grohe, C., Johnson, B. E., Kim, T. M., Hiltermann, T. J. N., Barlesi, F., Goto, Y., Gunnarsson, O., Overbeck, T., Reguart, N., Wermke, M., de Castro, G., Felip, E., Greystoke, A., Solomon, B. J., Deudon, S., Louveau, A. .-L., Passos, V., & Tan, D. S. W. (2020). CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC. Oncology Research and Treatment, 43(SUPPL 4), 152-152.

Grohe, C. ; Johnson, B. E. ; Kim, T. M. et al. / CANOPY-1 : Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC. In: Oncology Research and Treatment. 2020 ; Vol. 43, No. SUPPL 4. pp. 152-152.

@article{b9f9d83522734c32b419d01afb7a80f4,

title = "CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC",

author = "C. Grohe and Johnson, {B. E.} and Kim, {T. M.} and Hiltermann, {T. J. N.} and F. Barlesi and Y. Goto and O. Gunnarsson and T. Overbeck and N. Reguart and M. Wermke and {de Castro}, G. and E. Felip and A. Greystoke and Solomon, {B. J.} and S. Deudon and Louveau, {A. -L.} and V. Passos and Tan, {D. S. W.}",

year = "2020",

month = oct,

language = "English",

volume = "43",

pages = "152--152",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

publisher = "KARGER",

number = "SUPPL 4",

}

Grohe, C, Johnson, BE, Kim, TM, Hiltermann, TJN, Barlesi, F, Goto, Y, Gunnarsson, O, Overbeck, T, Reguart, N, Wermke, M, de Castro, G, Felip, E, Greystoke, A, Solomon, BJ, Deudon, S, Louveau, A-L, Passos, V & Tan, DSW 2020, 'CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC', Oncology Research and Treatment, vol. 43, no. SUPPL 4, pp. 152-152.

CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC. / Grohe, C.; Johnson, B. E.; Kim, T. M. et al.
In: Oncology Research and Treatment, Vol. 43, No. SUPPL 4, 10.2020, p. 152-152.

Research output: Contribution to journal › Meeting Abstract › Academic

TY - JOUR

T1 - CANOPY-1

T2 - Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC

AU - Grohe, C.

AU - Johnson, B. E.

AU - Kim, T. M.

AU - Hiltermann, T. J. N.

AU - Barlesi, F.

AU - Goto, Y.

AU - Gunnarsson, O.

AU - Overbeck, T.

AU - Reguart, N.

AU - Wermke, M.

AU - de Castro, G.

AU - Felip, E.

AU - Greystoke, A.

AU - Solomon, B. J.

AU - Deudon, S.

AU - Louveau, A. -L.

AU - Passos, V.

AU - Tan, D. S. W.

PY - 2020/10

Y1 - 2020/10

M3 - Meeting Abstract

SN - 2296-5270

VL - 43

SP - 152

EP - 152

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

IS - SUPPL 4

ER -

Grohe C, Johnson BE, Kim TM, Hiltermann TJN, Barlesi F, Goto Y et al. CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC. Oncology Research and Treatment. 2020 Oct;43(SUPPL 4):152-152.